Pathfinder Cell Therapy

PFND · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About PFND

Pathfinder Cell Therapy, Inc. is a development stage regenerative medicine company. The company is headquartered in Cambridge, Massachusetts. The firm is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The firm is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The firm has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The firm has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.

Employees
1
Headquarters
Cambridge, Massachusetts
Listed
Sep 22, 1992
Sector
Health Care
Industry
Biotechnology

PFND key statistics

Market cap
667
Price-earnings ratio
—
Dividend yield
—
Average volume
5.50K
Volume
1.00K
Open price
$0.00
High today
$0.00
Low today
$0.00
52 Week high
$0.00
52 Week low
$0.00

Pathfinder Cell Therapy (PFND) at a glance

As of Dec 29, 2025, Pathfinder Cell Therapy (PFND) shares are priced at $0.00, giving the company a market cap of 667.

Volume so far is 1.00K shares, below the average of 5.50K shares a day.

Pathfinder Cell Therapy met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY99 it reported -$0.08 per share against an estimate of -$0.1224.

PFND earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 42.7% on average.

  1. Q3 FY97: reported -$0.20 per share against an estimate of -$0.255
  2. Q4 FY97: reported -$0.37 per share against an estimate of -$0.2652
  3. Q1 FY98: reported -$0.21 per share against an estimate of -$0.3213
  4. Q2 FY98: reported -$0.33 per share against an estimate of -$0.3366
  5. Q3 FY98: reported -$0.29 per share against an estimate of -$0.1836
  6. Q4 FY98: reported -$0.13 per share against an estimate of $0.2244
  7. Q1 FY99: reported $0.04 per share against an estimate of -$0.1938
  8. Q2 FY99: reported -$0.08 per share against an estimate of -$0.1224

Similar companies

Companies in the same industry as Pathfinder Cell Therapy

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.